Management of Tibial Hematoma in Elderly Patients on Apixaban

Immediate Anticoagulation Management

The American College of Cardiology recommends suspending apixaban immediately in patients with non-life-threatening tibial hematoma, and monitoring the extension of the hematoma, evaluating renal function, and planning the resumption of anticoagulation once adequate hemostasis is achieved 1.
The European Society of Cardiology suggests that agents for reversal (andexanet alfa or Kcentra) are not necessary for stable lower limb hematomas, as they are reserved for life-threatening bleeding with hemodynamic instability 1, 2.
The half-life of apixaban is approximately 12 hours, so the anticoagulant effect will naturally decrease within 24-48 hours of suspension 2.

The American Heart Association recommends evaluating renal function (creatinine, creatinine clearance) immediately, as renal deterioration increases apixaban accumulation and bleeding risk 1.
In elderly patients with renal insufficiency, even limited renal clearance (~27% for apixaban) can cause high drug levels 1.

The World Journal of Emergency Surgery suggests monitoring vital signs, particularly blood pressure and heart rate, to exclude hemodynamic instability that would require urgent hospitalization 3.
Evaluating the presence of compartment syndrome (disproportionate pain, paresthesia, pallor, absence of distal pulses) is crucial, as it represents a surgical emergency 3.

The American College of Cardiology recommends checking hemoglobin/hematocrit every 24-48 hours to quantify blood loss 2.
A decrease in hemoglobin ≥2 g/dL indicates significant bleeding that may require hospitalization 2.

The World Journal of Emergency Surgery suggests applying local compression, elevating the limb, and using ice in the first 48 hours, and avoiding physical activity and trauma to the affected limb 3.
Administering paracetamol (acetaminophen) for pain control, while avoiding NSAIDs that could increase the risk of bleeding, is recommended 3.

The American College of Cardiology recommends calculating the CHA₂DS₂-VASc score to stratify thromboembolic risk during anticoagulation suspension 1.
In patients with atrial fibrillation, the thromboembolic risk is substantial, and prolonged anticoagulation suspension significantly increases the risk of stroke 1.

The American College of Cardiology suggests that anticoagulation can be interrupted for up to 1 week for procedures with bleeding risk without replacement with heparin in patients without mechanical valves 4, 5.
However, apixaban should be resumed as soon as adequate hemostasis is achieved, without waiting for a specific time interval, given the high thromboembolic risk 1.

The American College of Cardiology recommends resuming apixaban when the hematoma has stabilized (no extension for 48 hours) and hemoglobin is stable 1.
The decision depends on the adequacy of hemostasis, the severity of the bleeding episode, and the CHA₂DS₂-VASc score 1.

The American College of Cardiology suggests re-evaluating the apixaban dose based on updated renal function, age (≥80 years), and body weight (≤60 kg) 6.
In patients with severe renal insufficiency (creatinine clearance <15 mL/min) or end-stage renal disease, apixaban is contraindicated 6.

The American College of Cardiology recommends not using reversal agents (andexanet alfa, Kcentra) for non-life-threatening bleeding, as they increase the risk of thromboembolism (10.3% vs 5.6%) 1, 2.
Not resuming apixaban too early before adequate hemostasis is achieved, risking hematoma re-expansion, is crucial 1.
Not prolonging anticoagulation suspension excessively, increasing the risk of ischemic stroke, is also important 1.